Bacillus calmette guerin induces fibroblast activation both directly and through macrophages in a mouse bladder cancer model

PLoS ONE

Volumn 5, Issue 10, 2010, Pages

  Lodillinsky, Catalina ^a   Langle, Yanina ^a   Guionet, Ariel ^b   Góngora, Adrián ^a   Baldi, Alberto ^a   Sandes, Eduardo O ^a   Casabé, Alberto ^a   Eiján, Ana María ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BCG VACCINE; COLLAGEN; FIBROBLAST GROWTH FACTOR 2; MITOGEN ACTIVATED PROTEIN KINASE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; PHOSPHATIDYLINOSITOL 3 KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLADDER CANCER; CANCER IMMUNOTHERAPY; CANCER TISSUE; CELL ACTIVATION; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL STRAIN 3T3; CONTROLLED STUDY; DRUG EFFECT; DRUG RESPONSE; FIBROBLAST; IN VIVO STUDY; INOCULATION; MACROPHAGE ACTIVATION; MALE; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WOUND HEALING; ANIMAL; BLADDER TUMOR; CYTOLOGY; DISEASE MODEL; DRUG ANTAGONISM; IMMUNOLOGY; PATHOLOGY; PHYSIOLOGY;

MURINAE; MUS; MYCOBACTERIUM BOVIS BCG;

ANIMALS; BCG VACCINE; CELL DIFFERENTIATION; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; FIBROBLAST GROWTH FACTOR 2; FIBROBLASTS; MACROPHAGES, PERITONEAL; MICE; NIH 3T3 CELLS; NITRIC OXIDE; URINARY BLADDER NEOPLASMS;

EID: 78149444540     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0013571     Document Type: Article

References (39)

1. Morales A, Eidinger D, Bruce AW (1976) Intracavitary Bacillus Calmette- Guerin in the treatment of superficial bladder tumors. J Urol 116: 180-183.
2. Sylvester RJ, Brausi MA, Kirkels WJ, Hoeltl W, Calais Da Silva F, et al. (2009) Long-Term Efficacy Results of EORTC Genito-Urinary Group Randomized Phase 3 Study 30911 Comparing Intravesical Instillations of Epirubicin, Bacillus Calmette-Guerin, and Bacillus Calmette-Guerin plus Isoniazid in Patients with Intermediate- and High-Risk Stage Ta T1 Urothelial Carcinoma of the Bladder. Eur Urol.
3. Smaldone MC, Gayed BA, Tomaszewski JJ, Gingrich JR (2009) Strategies to enhance the efficacy of intravescical therapy for non-muscle invasive bladder cancer. Minerva Urol Nefrol 61: 71-89.
4. Riemensberger J, Bohle A, Brandau S (2002) IFN-gamma and IL-12 but not IL-10 are required for local tumour surveillance in a syngeneic model of orthotopic bladder cancer. Clin Exp Immunol 127: 20-26.
5. Suttmann H, Riemensberger J, Bentien G, Schmaltz D, Stockle M, et al. (2006) Neutrophil granulocytes are required for effective Bacillus Calmette-Guerin immunotherapy of bladder cancer and orchestrate local immune responses. Cancer Res 66: 8250-8257.
6. Mosser DM, Edwards JP (2008) Exploring the full spectrum of macrophage activation. Nat Rev Immunol 8: 958-969.
7. Prescott S, Jackson AM, Hawkyard SJ, Alexandroff AB, James K (2000) Mechanisms of action of intravesical bacille Calmette-Guerin: local immune mechanisms. Clin Infect Dis 31(Suppl 3): S91-93.
8. Saban MR, O'Donnell MA, Hurst RE, Wu XR, Simpson C, et al. (2008) Molecular networks discriminating mouse bladder responses to intravesical bacillus Calmette-Guerin (BCG), LPS, and TNF-alpha. BMC Immunol 9: 4
9. Sandes EO, Faletti AG, Riveros MD, Vidal Mdel C, Gimenez L, et al. (2005) Expression of inducible nitric oxide synthase in tumoral and non-tumoral epithelia from bladder cancer patients. Nitric Oxide 12: 39-45.
10. Mitropoulos D, Petsis D, Kyroudi-Voulgari A, Kouloukoussa M, Zervas A, et al. (2005) The effect of intravesical Bacillus Calmette-Guerin instillations on the expression of inducible nitric oxide synthase in humans. Nitric Oxide 13: 36-41.
11. Alvarez V, Lodillinsky C, Umerez S, Sandes E, Eijan AM (2005) Inhibition of bacillus Calmette-Guerin-induced nitric oxide in bladder tumor cells may improve BCG treatment. Int J Mol Med 16: 565-571.
12. Barrientos S, Stojadinovic O, Golinko MS, Brem H, Tomic-Canic M (2008) Growth factors and cytokines in wound healing. Wound Repair Regen 16: 585-601.
13. Singer AJ, Clark RA (1999) Cutaneous wound healing. N Engl J Med 341: 738-746.
14. Strutz F, Zeisberg M, Hemmerlein B, Sattler B, Hummel K, et al. (2000) Basic fibroblast growth factor expression is increased in human renal fibrogenesis and may mediate autocrine fibroblast proliferation. Kidney Int 57: 1521-1538.
15. Chen F, Zhang G, Iwamoto Y, See WA (2005) BCG directly induces cell cycle arrest in human transitional carcinoma cell lines as a consequence of integrin cross-linking. BMC Urol 5: 8.
16. Sandes E, Lodillinsky C, Cwirenbaum R, Arguelles C, Casabe A, et al. (2007) Cathepsin B is involved in the apoptosis intrinsic pathway induced by Bacillus Calmette-Guerin in transitional cancer cell lines. Int J Mol Med 20: 823-828.
17. Serini G, Gabbiani G (1999) Mechanisms of myofibroblast activity and phenotypic modulation. Exp Cell Res 250: 273-283.
18. Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA (2002) Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol 3: 349-363.
19. Skalli O, Ropraz P, Trzeciak A, Benzonana G, Gillessen D, et al. (1986) A monoclonal antibody against alpha-smooth muscle actin: a new probe for smooth muscle differentiation. J Cell Biol 103: 2787-2796.
20. Schultz GS, Wysocki A (2009) Interactions between extracellular matrix and growth factors in wound healing. Wound Repair Regen 17: 153-162.
21. Coleman AB, Momand J, Kane SE (2000) Basic fibroblast growth factor sensitizes NIH 3T3 cells to apoptosis induced by cisplatin. Mol Pharmacol 57: 324-333.
22. Schafer M, Werner S (2008) Cancer as an overhealing wound: an old hypothesis revisited. Nat Rev Mol Cell Biol 9: 628-638.
23. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, et al. (2008) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 54: 303-314.
24. Shelley MD, Mason MD, Kynaston H (2010) Intravesical therapy for superficial bladder cancer: A systematic review of randomised trials and meta-analyses. Cancer Treat Rev.
25. Friday BB, Adjei AA (2008) Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy. Clin Cancer Res 14: 342-346.
26. Jiang BH, Liu LZ (2009) PI3K/PTEN signaling in angiogenesis and tumorigenesis. Adv Cancer Res 102: 19-65.
27. Allavena P, Sica A, Garlanda C, Mantovani A (2008) The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance. Immunol Rev 222: 155-161.
28. Isenberg JS (2004) Nitric oxide modulation of early angiogenesis. Microsurgery 24: 385-391.
29. Aoi Y, Terashima S, Ogura M, Nishio H, Kato S, et al. (2008) Roles of nitric oxide (NO) and NO synthases in healing of dextran sulfate sodium-induced rat colitis. J Physiol Pharmacol 59: 315-336.
30. Murakami H, Shinomiya N, Kikuchi T, Fujikawa K, Nemoto K (2005) Differential sensitivity to NO-induced apoptosis between anterior cruciate and medial collateral ligament cells. J Orthop Sci 10: 84-90.
31. Zhang S, Xu G, Luo L (1995) [Enhancing effects of the supernatant of pulmonary alveolar macrophages stimulated by BCG on proliferation on pulmonary fibroblasts]. Zhonghua Jie He He Hu Xi Za Zhi 18: 26-28, 62-23.
32. Chen M, Zhang G, Yi M, Chen X, Li J, et al. (2009) Effect of UVA irradiation on proliferation and NO/iNOS system of human skin fibroblast. Zhong Nan Da Xue Xue Bao Yi Xue Ban 34: 705-711.
33. Dvorak HF (1986) Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 315: 1650-1659.
34. Amadeu TP, Costa AM (2006) Nitric oxide synthesis inhibition alters rat cutaneous wound healing. J Cutan Pathol 33: 465-473.
35. Turner N, Grose R (2010) Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 10: 116-129.
36. Babaei S, Teichert-Kuliszewska K, Monge JC, Mohamed F, Bendeck MP, et al. (1998) Role of nitric oxide in the angiogenic response in vitro to basic fibroblast growth factor. Circ Res 82: 1007-1015.
37. Malavaud B, Pedron S, Sordello S, Mazerolles C, Billottet C, et al. (2004) Direct FGF receptor 1 activation through an anti-idiotypic strategy mimicks the biological activity of FGF-2 and inhibits the progression of the bladder carcinoma derived from NBT-II cells. Oncogene 23: 6769-6778.
38. Brosman SA (1982) Experience with bacillus Calmette-Guerin in patients with superficial bladder carcinoma. J Urol 128: 27-30.
39. Cristina C, Diaz-Torga G, Gongora A, Guida MC, Perez-Millan MI, et al. (2007) Fibroblast growth factor-2 in hyperplastic pituitaries of D2R knockout female mice. Am J Physiol Endocrinol Metab 293: E1341-1351.